Recently, common noncoding variants in the TCF7L2 gene were strongly associated with increased risk of type 2 diabetes in samples from Iceland, Denmark, and the U.S. We genotyped 13 single nucleotide polymorphisms (SNPs) across TCF7L2 in 8,310 individuals in family-based and case-control designs from Scandinavia, Poland, and the U.S. We convincingly confirmed the previous association of TCF7L2 SNPs with the risk of type 2 diabetes (rs7903146T odds ratio 1.40 [95% CI 1.30 -1.50], P ‫؍‬ 6.74 ؋ 10 ؊20 ). In nondiabetic individuals, the risk genotypes were associated with a substantial reduction in the insulinogenic index derived from an oral glucose tolerance test (risk allele homozygotes have half the insulin response to glucose of noncarriers, P ‫؍‬ 0.003) but not with increased insulin resistance. These results suggest that TCF7L2 variants may act through insulin secretion to increase the risk of type 2 diabetes. Diabetes 55:2890 -2895, 2006 T ype 2 diabetes is highly heritable, but known variants explain only a small fraction of the overall genetic risk in the population. Recently, Grant et al. (1) reported a strong association of variants in TCF7L2 with increased risk of type 2 diabetes in an Icelandic sample, and this association was confirmed in Caucasian samples from Denmark and the U.S. (combined odds ratio [OR] 1.56, P ϭ 4.7 ϫ 10 Ϫ18 ). Testing of this association in other well-phenotyped samples is needed to 1) validate the association, 2) estimate the true effect size, and 3) identify effects on intermediate traits that may suggest how TCF7L2 variants act (e.g., through changes in insulin secretion, insulin resistance, BMI, waist-to-hip ratio).
T ype 2 diabetes is highly heritable, but known variants explain only a small fraction of the overall genetic risk in the population. Recently, Grant et al. (1) reported a strong association of variants in TCF7L2 with increased risk of type 2 diabetes in an Icelandic sample, and this association was confirmed in Caucasian samples from Denmark and the U.S. (combined odds ratio [OR] 1.56, P ϭ 4.7 ϫ 10 Ϫ18 ). Testing of this association in other well-phenotyped samples is needed to 1) validate the association, 2) estimate the true effect size, and 3) identify effects on intermediate traits that may suggest how TCF7L2 variants act (e.g., through changes in insulin secretion, insulin resistance, BMI, waist-to-hip ratio).
TCF7L2 has been implicated as a member of the Wnt signaling pathway and was previously well studied only in colon cancer. However, based on its role in intestinal cells (2), Grant et al. (1) proposed that variants of TCF7L2 may alter levels of glucagon-like peptide 1, which influences insulin secretion from the ␤-cells of the pancreas. Thus, one hypothesis is that TCF7L2 might influence the risk of type 2 diabetes by influencing insulin secretion. Alternatively, a gene increasing the risk of diabetes could act through insulin action or through currently unknown mechanisms.
To evaluate these questions, we selected tag SNPs to capture common variation in a 64.6-kb region of strong linkage disequilibrium surrounding the most significant association signal and spanning intron 3, exon 4, and intron 4 of TCF7L2. We genotyped 13 tag SNPs that capture 32 of 44 variants with r 2 Ͼ 0.8 (mean r 2 Ͼ 0.985) in the phase II HapMap CEU population (3); all 5 SNPs that were most highly correlated with the DG10S478 allele X in the original report (1) were directly genotyped.
The tag SNPs were genotyped in well-characterized family-based and case-control samples from Scandinavia, Poland, and the U.S.; phenotypic characteristics of all samples are described in Table 1 . We included five previously described patient samples that have formed the basis of multiple previous publications from our research group: 333 Swedish and Finnish trios; 2 Scandinavian case-control samples with 918 and 1,010 subjects, respec-tively; a Polish case-control sample with 2,018 subjects; and a U.S. Caucasian case-control sample with 2,452 individuals (4 -11) . A smaller fraction of the samples studied have not previously been described: 1) a casecontrol sample (444 subjects) and 130 discordant sibpairs from Botnia (a Swedish-speaking isolate of Finland) and 2) a case-control sample (266 subjects) and 106 discordant sibpairs from Sweden and Finland. All Scandinavian casecontrol samples were matched for age, sex, BMI, and geographic region (described in more detail in RESEARCH DESIGN AND METHODS).
Association of SNPs in TCF7L2 with type 2 diabetes was strongly confirmed in these samples (Table 2 and online  appendix Table 1 [available at http://diabetes.diabetes journals.org]). We found that rs7903146 was most significantly associated with the risk of type 2 diabetes (OR 1.40 [95% CI 1.30 -1.50], P ϭ 6.74 ϫ 10 Ϫ20 ) in agreement with the original report (best SNP) (1). Heterozygous and homozygous carriers of the risk allele had genotype relative risks of 1.40 (1.27-1.55) (P ϭ 3.22 ϫ 10 Ϫ11 ) and 1.86 (1.55-2.23) (P ϭ 1.38 ϫ 10 Ϫ11 ) relative to noncarriers, which is consistent with an additive model. Overall, given that the original report was highly significant (P ϭ 10 Ϫ18 ) (1), our results provided an independent P value of 10 Ϫ20 , and Groves et al. (unpublished observations) observed a P value of 10 Ϫ14 ; this association is by far the most convincing and broadly relevant risk factor for type 2 diabetes yet found in the human population. Data are means Ϯ SD. Plasma glucose was measured at fasting and 2 h after an OGTT. *HbA 1c (A1C) ϭ 6.5 Ϯ 1.5%; †A1C ϭ 7.9 Ϯ 1.3%; ‡A1C ϭ 8.0 Ϯ 3.1%. C/C, case/control subjects; ND, not determined; sIGT, severe IGT. The strongest single variant (rs7903146) was individually significant (P Ͻ 0.05) in the six largest samples (including all previously published trio and case-control samples) and trended in the expected direction in the three smaller remaining samples (Table 3) . We have previously published a lack of association to many candidate genes in these samples (4 -8,10,11); replication of TCF7L2 association in each subsample provides a positive control for those previous studies, clearly demonstrating that the samples can be used to distinguish true diabetes genes of this magnitude and robustness from statistical fluctuations. To test if the best result was the only signal of association observed at this locus, we performed logistic regression analysis conditional on rs7903146. No additional signal of association was observed (data not shown), suggesting that the entire signal observed stems from rs7903146 or from a closely correlated variant.
We tested for epistasis between TCF7L2 rs7903146 and two other common variants known to be causally associated with the risk of type 2 diabetes: peroxisome proliferator-activated receptor ␥ P12A and Kir6.2 E23K (4, 5, 12) . No significant genetic interactions were seen (online appendix Ϫ7 ; P homogeneity ϭ 0.20). Furthermore, in case subjects, TCF7L2 genotypes did not associate with the age of onset of diabetes (n ϭ 1,856, mean [ϮSD] TT ϭ 55 Ϯ 11, TC ϭ 55 Ϯ 12, and CC ϭ 56 Ϯ 12; P ϭ 0.64). In addition, no significant association to BMI was observed (Table 4) . Thus, while some variants may prove 
TCF7L2 ASSOCIATED WITH TYPE 2 DIABETES
to be heterogeneous, associated only in substrata of sex, BMI, or other genotypes, common variation in TCF7L2 is associated with type 2 diabetes across the measured covariates. The order and relative contributions of defects in insulin resistance and insulin secretion to the pathogenesis of type 2 diabetes remain controversial (13, 14) . Some postulate that type 2 diabetes is caused primarily by defects in insulin resistance, followed by a failure of pancreatic ␤-cells to compensate for increased insulin demand (15) . Conversely, type 2 diabetes genes identified thus far (the maturity-onset diabetes of the young genes that cause monogenic forms of type 2 diabetes and Kir6.2) act through reduced insulin secretion without insulin resistance in carriers before the onset of disease (16, 17) . Each additional gene that is truly associated with type 2 diabetes helps inform the relative contributions of these two mechanisms.
We found no effect of TCF7L2 rs7903146 on oral glucose tolerance test (OGTT)-derived measures of insulin resistance in 995 nondiabetic individuals (Table 4) . We did see a dramatic effect, however, on insulin secretion as measured by the OGTT (Table 4) . The OGTT provides rough measures of insulin secretion and resistance and has been widely used in clinical investigations of type 2 diabetes. Individuals homozygous for the rs7903146 risk allele have a significant 50% reduction in insulinogenic index (P ϭ 0.003) and insulin disposition index (P ϭ 0.004). We also observed a significant reduction in the area under the curve (AUC) for insulin during the OGTT (P ϭ 0.0007) and AUC insulin /AUC glucose (P ϭ 0.002), suggesting that the polymorphism not only influences the early insulin response to glucose but also could have an effect on the capacity of the ␤-cells to secrete insulin. These associations are stronger in risk allele homozygotes than in heterozygous carriers, and a trend is seen in heterozygous carriers compared with noncarriers.
Our results replicate the strong association of TCF7L2 variants with the risk of type 2 diabetes. The risk model for the most significantly associated SNP, rs7903146, was slightly weaker than the original report, perhaps because the magnitude of the risk effect may have been overestimated by Grant et al. (1) , which was expected due to the winners curse. Consistent with this, Groves et al. (unpublished observations) estimate an effect size similar to that in our study (OR 1.36 and 1.40, in both replications, vs. 1.54 for the same SNP in the original report). Nevertheless, TCF7L2 variation contributes more powerfully to increased risk of type 2 diabetes than any other gene identified thus far. Consistent replication across European populations confirms that the causal TCF7L2 variant influences disease risk reproducibly, without the need to yet invoke population-specific effects.
We observed an insulin secretion defect in nondiabetic individuals homozygous for risk alleles of TCF7L2, suggesting that as in maturity-onset diabetes of the young and the common E23K polymorphism in Kir6.2, the primary defect attributable to a common variation in the TCF7L2 region is reduced insulin secretion rather than insulin resistance (12, 16, 17) . However, OGTT measures used here provides only rough estimates of insulin secretion, and follow-up work will be necessary to understand the nature of the defect in insulin secretion and any possible effects on insulin action.
TCF7L2 has not previously been implicated in type 2 diabetes and would not have been an obvious diabetes gene candidate. (A PubMed search for the keywords "TCF7L2" or "TCF4" reveals 218 articles but none that share the term "diabetes" before the Grant et al. [1] publication.) The discovery of this gene reinforces that type 2 diabetes is an endocrine disease with its origin in multiple organ systems, now possibly including the intestine. Post hoc, because TCF7L2 activates glucagon-like peptide 1 in a cell-specific manner, a putative mechanism to influence blood glucose homeostasis could be proposed, and reduced insulin secretion observed here is consistent with this mechanism (1). However, the causal variant or functional defect in TCF7L2 has not yet been found. (It could be rs7903146 itself, a proxy within a broader region of this gene, or a proxy even in an adjacent gene.) More extensive genotyping and sequencing is clearly warranted, as are functional studies of the most associated alleles to document that they function through TCF7L2 rather than some adjacent gene.
The identification of this gene has interesting implications for the several diabetes whole-genome association studies planned in the coming year. There has been much speculation that common variants responsible for common diseases such as type 2 diabetes, at most, exert extremely modest effects, owing to an underlying complex genetic architecture (18 -20) . Some have even questioned whether disease-influencing common variants exist or can be found with linkage disequilibrium approaches (21, 22) . Grant et al. (1) discovered an association to TCF7L2 during a follow-up of a putative linkage peak, but as they state, the finding is likely coincidental since "the median allele-sharing LOD score generated with our previous familial samples is less than 0.1." That is, this variant could not possibly have generated the linkage peak but could be (and was) found by systematic studies of common variation for the association with type 2 diabetes. Unless TCF7L2 is the only such gene in the genome, which is unlikely given that a focused search of ϳ10.5 Mb led coincidentally to its discovery, more diabetes genes of similar effect are likely to be found by ongoing wholegenome association studies.
RESEARCH DESIGN AND METHODS
The diabetic samples include a previously described sample of 333 Scandinavian parent-offspring trios (163 offspring with impaired fasting glucose, 36 with impaired glucose tolerance [IGT] , and 134 with type 2 diabetes) (4) and two previously described Scandinavian case-control samples consisting of 954 and 1,028 subjects, individually matched for age, sex, BMI, and geographic region of origin (4, 5) . World Health Organization 1998 definitions of type 2 diabetes, IGT, impaired fasting glucose, and normal glucose tolerance (NGT) were used for these samples, and severe IGT was defined as 2-h OGTT plasma glucose Ͼ8.5 mmol/l but Ͻ10 mmol/l. This study also includes two previously described case-control samples from Poland (2,018 subjects) and the U.S. (2,452 subjects) individually matched for sex, age, and geographic origin, both collected by Genomics Collaborative (6, 11) . For these Polish and U.S. samples, case subjects met the American Diabetes Association 2003 criteria for type 2 diabetes, and control subjects had fasting plasma glucose Ͻ7 mmol/l. Finally, the study included four newly selected Scandinavian samples: 1) a case-control sample (444 subjects) from Botnia (a Swedish-speaking isolate of Finland) individually matched by age, sex, and BMI; 2) 130 sibpairs from Botnia, discordant for type 2 diabetes; 3) a case-control sample from Sweden and Finland (266 subjects) individually matched by age, sex, BMI, and geographic origin; and 4) 106 sibpairs discordant for type 2 diabetes from Sweden and Finland. For the new case-control and family-based samples, diabetic case subjects were defined by the American Diabetes Association 2003 criteria, had an age of onset Ն35 years, and were GAD antibody negative. Control subjects had NGT (fasting plasma glucose Ͻ6.1 mmol/l and 2-h OGTT plasma glucose Ͻ7.8 mmol/l). Age matching required that control subjects be normal glucose tolerant at age Ͻ5 years from onset age of matched case. For discordant sibpairs, the youngest sibling who fulfilled the case inclusion criteria was matched with the eldest normal glucose tolerant sibling. Case and control subjects were recruited from the previously described Botnia Study, which includes families from the Botnia region on the western coast of Finland and families from other parts of Finland and Sweden (23) . All patient samples were approved by the human subject institutional review board at respective institutions, and informed consent was obtained from all subjects. Insulin measures during the OGTT were available for a subset of individuals as previously described (7, 11) (AUCs determined by the trapezoidal method) . Genotyping. Patient DNA was isolated from whole blood, whole genome amplified using REPLI-G (Qiagen), and purified using the Nucleofast (Clontech). Genotyping was performed by primer extension of multiplex products with detection by MALDI-TOF mass spectroscopy using a Sequenom platform. Genotyping success rate was 99%, and concordance rate, based on 889 duplicate comparisons for each of the 13 SNPs, was 99.58%. Statistical analysis. Tag SNPs were selected using Tagger (24); 12 SNPs were untested. Simple 2 analysis was used to test the association of SNPs with type 2 diabetes in the matched case-control subjects, a transmission disequilibrium test was performed in the trios (25) , and the discordant allele test was carried out in the sibpairs (26) . Results from each sample were combined by Mantel-Haenszel meta-analysis of ORs; homogeneity was tested using the Breslow Day test, and no heterogeneity was found. Logistic regression for each SNP with diabetes-affected status was performed conditionally on rs7903146 using Whap (http://pngu.mgh.harvard.edu/ϳpurcell/ whap). For epistasis analysis, pairwise combinations of SNPs rs7903146 with peroxisome proliferator-activated receptor ␥ P12A and Kir6.2 E23K were tested for association with type 2 diabetes using PLINK (http://pngu.mgh. harvard.edu/ϳpurcell/plink). Log-transformed quantitative traits were compared by ANOVA across three genotypic classes of rs7903146; two-tailed t tests were performed for other models/risk estimates. Unadjusted P nominal values are reported; results were similar after adjustment for sex, age, and BMI.
